Biophan CEO Michael Wiener Presented at Las Vegas Money Show; CEO Delivered Presentation on Company's Strategy to Generate Revenue Through Intellectual Property Ownership.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation medical technology, has announced that the Company participated as an exhibitor and presenter at the 2005 Money Show in Las Vegas, Nevada, which ran from May 10th through May 12th. CEO Michael Weiner made a presentation at the show about the Company's intellectual-property-driven revenue growth strategy and its advanced solutions for the biomedical marketplace.

The Money Show is in its 17th year and attracts accredited investors from the United States, Canada and Europe who are looking for new ways to invest their equity. Over 200 companies exhibited at the Show, and this year there was a special focus section on emerging technology companies.

"This was a great opportunity for Biophan to reach a large audience of potential investors and discuss our strategy to build shareholder value through our extensive intellectual property portfolio," said Mr. Weiner. "Our business plan is designed to leverage our next-generation nanotechnology and other solutions to create useful and successful products for several multi-billion-dollar biomedical marketplaces, from advanced drug-delivery systems to solutions that enhance stents that have unique features to enable accurate Magnetic Resonance Imaging."

The presentation Mr. Weiner delivered at the Money Show can be viewed online at http://www.trilogy-capital.com/tcp/biophan/presentation.html. Click on the "Multimedia Content" link.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.